Plain-English translation of NCT07514962 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →This trial is testing cangrelor, a blood-thinning medication, in patients who are having a special type of heart bypass surgery called minimally invasive coronary artery bypass (MIDCAB). The surgery is designed to restore blood flow to a blocked artery in the heart using a smaller incision than traditional open-heart surgery. Researchers want to see if giving this medication continuously during and after surgery is safe and helps protect the heart without causing excessive bleeding.
During heart bypass surgery, blood clots can form and damage the heart or brain. While standard blood thinners like aspirin have been used for years, this medication works faster and differently, which might provide better protection during this newer, less invasive surgical technique.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would be admitted to the hospital and have your blood platelet function tested daily to ensure the medication is working properly. Your surgery would be scheduled at least 24 hours after the medication is started. During and after surgery, doctors would monitor your vital signs, heart rhythm, and blood work closely, and measure how much bleeding occurs. You would stay in the intensive care unit for monitoring, with daily blood tests and check-ups to ensure your safety.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
Switzerland